Drugs Archives - Page 24 of 66 - ��ýҕ�l Health News

KHN’s ‘What the Health?’: Compromise Is Coming — Maybe

Democratic negotiators on Capitol Hill appear to be nearing a compromise on President Joe Biden’s social spending agenda, spurred partly by Democratic losses on Election Day in Virginia. Meanwhile, the Supreme Court hints it might allow abortion providers to sue Texas over its restrictive new ban. But the relief, if it comes, could be short-lived if the court uses a second case, challenging a law in Mississippi, to weaken or overturn Roe v. Wade. Alice Miranda Ollstein of Politico, Margot Sanger-Katz of The New York Times and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Rae Ellen Bichell, who reported and wrote the latest KHN-NPR “Bill of the Month” feature about an emergency bill for a nonemergency birth.

Nov. 4, 2021

What Do We Really Know About Vaccine Effectiveness?

Reports of waning effectiveness and mixed messages about booster shots fuel the politicization of vaccination.

By Julie Appleby

Nov. 2, 2021

Nursing Home Residents Overlooked in Scramble for Covid Antibody Treatments

A federal allocation plan meant to ensure equitable distribution of powerful monoclonal antibody treatments for high-risk patients fails to prioritize nursing home residents, a population that remains particularly vulnerable even after vaccination.

By JoNel Aleccia

Nov. 1, 2021

Podcast

KHN’s ‘What the Health?’: Biden Social-Spending ‘Framework’ Pulls Back on Key Health Pledges

President Joe Biden unveiled a compromise “Build Back Better” framework shortly before taking off for key meetings in Europe, but it’s unclear whether the framework can win the votes of all Democrats in the House and Senate, and it leaves out some of the party’s health priorities, notably significant provisions to lower prescription drug prices. Meanwhile, younger children may soon be eligible for covid vaccines. Joanne Kenen of Politico and Johns Hopkins, Sarah Karlin-Smith of the Pink Sheet and Rachana Pradhan of KHN join KHN’s Julie Rovner to discuss these issues and more.

Oct. 28, 2021

Pharma Cash to Congress

Pharma Campaign Cash Delivered to Key Lawmakers With Surgical Precision

With an eye to shutting down Medicare drug price negotiations, drug companies and their lobbying groups gave roughly $1.6 million in the first six months of 2021, with Democrats edging closer than they have in a decade to Republicans’ total haul.

By Victoria Knight, Rachana Pradhan, and Elizabeth Lucas

Oct. 27, 2021

Watch: Going Beyond the Script of ‘Dopesick’ and America’s Real-Life Opioid Crisis

KHN teamed up with Hulu for a discussion of America's opioid crisis, following the Oct. 13 premiere of the online streaming service’s new series “Dopesick.”

Oct. 18, 2021

The Public Backs Medicare Rx Price Negotiation Even After Hearing Both Sides’ Views

But Americans generally have little confidence that the White House or Congress will recommend the right thing, a new poll shows.

By Amanda Michelle Gomez

Oct. 12, 2021

What the Stalemate on Capitol Hill Means for Your Drug Prices

Despite big 2020 campaign promises to deliver lower costs on prescription drugs, Democrats have failed to unite around a legislative plan.

By Sarah Jane Tribble

Oct. 1, 2021

Navigating Aging

Alzheimer’s Drug Targets People With Mild Cognitive Impairment. What Does That Mean?

The condition can be an early signal of Alzheimer’s disease, but not always. Other health concerns could be causing thinking or memory problems, and the new drug, Aduhelm, would not be appropriate for those patients.

By Judith Graham

Sept. 29, 2021

KHN On Air

From the FDA’s Empty Seat to Chock-Full ICUs, Journalists Recap the Week’s Stories

KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.

Sept. 25, 2021

COVID-19

A Daily Pill to Treat Covid Could Be Just Months Away, Scientists Say

At least three promising antiviral treatments for covid-19 are being tested in clinical trials, with results expected as soon as late fall or winter.

By JoNel Aleccia

Sept. 24, 2021

Podcast

KHN’s ‘What the Health?’: The Autumn of Democrats’ Discontent

Congress is back in session with a short time to finish a long to-do list, including keeping the government operating and paying its bills. Hanging in the balance is President Joe Biden’s entire domestic agenda, including major changes proposed for Medicare, Medicaid and the Affordable Care Act. Meanwhile, the new Texas abortion law that bans the procedure early in pregnancy is prompting action in Washington. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews former FDA Commissioner Scott Gottlieb about his new book on the covid-19 pandemic.

Sept. 23, 2021

Biosimilar Drugs Are Cheaper Than Biologics. Are They Similar Enough to Switch?

Biologic drugs, made from living organisms, and the cheaper biosimilar drugs that mimic them are more complex than chemical drugs and their generic counterparts. The Food and Drug Administration says biosimilars are as safe and effective as the biologics, and doctors agree — but they are cautious about changing the treatment regimen of patients doing well.

By Michelle Andrews

Sept. 23, 2021

Public Health Experts ‘Flabbergasted’ That Biden Still Hasn’t Picked an FDA Chief

The Food and Drug Administration has been mired in controversies related to drug approvals and covid vaccines, all without a permanent leader.

By Rachana Pradhan

Sept. 22, 2021

KHN Impact

Congress Cites KHN Investigation in Probe of National Academies

The House oversight committee is requesting conflict-of-interest disclosure forms from a National Academies committee studying organ transplants. KHN previously reported on apparent conflicts among members of a committee studying drug waste.

By Christina Jewett and JoNel Aleccia

Sept. 21, 2021

Podcast

KHN’s ‘What the Health?’: Much Ado About Drug Prices

Democrats have hit a snag in their effort to compile a $3.5 trillion social-spending bill this fall — moderates are resisting support for Medicare drug price negotiation provisions that would pay for many of the measure’s health benefit improvements. Meanwhile, the new abortion restrictions in Texas have moved the divisive issue back to the political front burner. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat and Shefali Luthra of The 19th join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interview’s KHN’s Phil Galewitz about the latest KHN-NPR “Bill of the Month” installment, about two similar jaw surgeries with very different price tags.

Sept. 16, 2021

COVID-19

These Governors Push Experimental Antibody Therapy — But Shun Vaccine and Mask Mandates

Governors in Southern states, amid a surge of delta-variant infections, are rushing to provide an experimental antibody cocktail therapy, even as they oppose measures like mask mandates and vaccine passports that health officials say can prevent infection in the first place.

By JoNel Aleccia

Aug. 25, 2021

From Uber Rides to Patient Advocates: What It Takes to Increase ER Addiction Treatment

Despite widespread consensus on the importance of addiction treatment in the ER, many hospitals fail to screen for substance use, offer medications to treat opioid use disorder or connect patients to follow-up care. But some are working to change that.

By Aneri Pattani

Aug. 25, 2021

COVID-19

‘We Sent a Terrible Message’: Scientists Say Biden Jumped the Gun With Vaccine Booster Plan

Many experts say the evidence doesn’t justify widespread booster shots for adults.

By Rachana Pradhan

Aug. 20, 2021

Podcast

KHN’s ‘What the Health?’: Booster Time

As the delta variant continues to spread around the U.S., the Biden administration is taking steps to authorize covid vaccine boosters, require nursing home workers to be vaccinated and protect school officials who want to require masks despite state laws banning those mandates. Meanwhile, the U.S. House is returning from its summer break early to start work on its giant budget bill, which includes a long list of health policy changes. Alice Miranda Ollstein of Politico, Margot Sanger-Katz of The New York Times and Kimberly Leonard of Business Insider join KHN’s Julie Rovner to discuss these issues and more.

Aug. 19, 2021

��ýҕ�l

Trump 2.0

Public Health

Audio Reports

Special Reports

More Topics

Drugs